Validation of α-synuclein Modifications in Parkinson's dIsoRder Evolution

Inclusion Criteria: * • For PD subjects * PD diagnosis according to MDS-UPDRS criteria and Hoehn and Yahr scale between I-IV (MED ON) for PD subjects * Willing to participate. Participation is always voluntary. * Willing and able to provide written informed consent to participate in the study or having a legal representative responsible for signing; the participant (or the legal representative) must understand the purpose, methods, and all information regarding the study. * For non-PD subjects * Normal neurological examination findings. * Medical record (recent and remote medical history) available and reviewable by clinicians during the entire study period. * Willing and able to provide written informed consent to participate in the study Exclusion Criteria: * • For PD and non-PD subjects * Clinically significant and severe cognitive decline and/or intellectual disability which can lead to impairment not caused by Parkinson's disease or any other disease that could better explain the patient's symptoms; The exclusion criteria involve neurological and neurodevelopmental disorders including disorders of the brain, spinal cord, peripheral nerve, and muscle (e.g. cerebral palsy, epilepsy \[seizure disorders\], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury). * Fever (Temperature 38.0 °C (tympanic)). * Acute infection (such as Flu, COVID-19) which could debilitate the patient and affect the data. * Individuals with concurrent infections requiring systemic antimicrobial and/or antiviral therapy at the pre-dose examinations (e.g. HepC, HIV, TB). * Life-threatening co-existing disease with life expectancy, which could lead to premature dropout. * Any other neurological or systemic conditions that could confound results.